Plasma autoantibodies associated with basal-like breast cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 9, 2015, Pages 1332-1340

  Wang, Jie ^a   Figueroa, Jonine D ^b   Wallstrom, Garrick ^a   Barker, Kristi ^a   Park, Jin G ^a   Demirkan, Gokhan ^a   Lissowska, Jolanta ^c   Anderson, Karen S ^a   Qiu, Ji ^a   LaBaer, Joshua ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CTAG1B ANTIBODY; CTAG2 ANTIBODY; DOK2 ANTIBODY; MESSENGER RNA; MN1 ANTIBODY; PIP4K2C ANTIBODY; PPHLN1 ANTIBODY; PSRC1 ANTIBODY; RNF216 ANTIBODY; TAS2R8 ANTIBODY; TP53 ANTIBODY; TRIM21 ANTIBODY; UNCLASSIFIED DRUG; WBP2NL ANTIBODY; ZBTB16 ANTIBODY; CARRIER PROTEIN; CELL SURFACE RECEPTOR; CTAG1B PROTEIN, HUMAN; CTAG2 PROTEIN, HUMAN; DOK2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MN1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PPHLN1 PROTEIN, HUMAN; PROTEIN P53; PSRC1 PROTEIN, HUMAN; RIBONUCLEOPROTEIN; RNF216 PROTEIN, HUMAN; SEMINAL PLASMA PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SS-A ANTIGEN; TAS2R8 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; WBP2NL PROTEIN, HUMAN; ZBTB16 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SCREENING; ANTIGENICITY; ARTICLE; BASAL LIKE BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; ISOELECTRIC POINT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLAND; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; CHEMISTRY; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; AUTOANTIBODIES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARRIER PROTEINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MEMBRANE PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHOPROTEINS; POLAND; PROTEIN ARRAY ANALYSIS; RECEPTORS, CELL SURFACE; RIBONUCLEOPROTEINS; RNA, MESSENGER; SEMINAL PLASMA PROTEINS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84941754824     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0047     Document Type: Article

References (57)

1. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007;4:415-23.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
3. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
4. Domingo L, Salas D, Zubizarreta R, Bare M, Sarriugarte G, Barata T, et al. Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Research 2014;16:11.
5. Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, Yaffe MJ, et al. Tumor characteristics associated with mammographic detection of breast cancer in the ontario breast screening program. J Natl Cancer Inst 2011;103:942-50.
6. Foulkes WD, Smith IE, Reis JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
7. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype. Clin Cancer Res 2008;14: 1368-76.
8. Metzger O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012;30: 1879-87.
9. Anderson KS, LaBaer J. The sentinel within: Exploiting the immune system for cancer biomarkers. J Proteome Res 2005;4:1123-33.
10. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkersblood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011;8:142-50.
11. Mange A, Lacombe J, Bascoul-Mollevi C, Jarlier M, Lamy PJ, Rouanet P, et al. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res 2012;18:1992-2000.
12. Wang XJ, Yu JJ, Sreekumar A, Varambally S, Shen RL, Giacherio D, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353: 1224-35.
13. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-6.
14. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, LaBaer J, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010;19: 859-68.
15. Miersch S, Bian XF, Wallstrom G, Sibani S, Logvinenko T, Wasserfall CH, et al. Serological autoantibody profiling of type 1 diabetes by protein arrays. J Proteomics 2013;94:486-96.
16. Wright C, Sibani S, Trudgian D, Fischer R, Kessler B, LaBaer J, et al.Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics 2012; 11:10.
17. Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011;10:85-96.
18. Anderson KS, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, et al. Autoantibody signature for the serologic detection of ovarian cancer. J Proteome Res 2015;14:578-86.
19. Ramachandran N, Hainsworth E, Bhullar B, Eisenstein S, Rosen B, Lau AY, et al. Self-assembling protein microarrays. Science 2004;305: 86-90.
20. Ramachandran N, Raphael JV, Hainsworth E, Demirkan G, Fuentes MG, Rolfs A, et al. Next-generation high-density self-assembling functional protein arrays. Nat Methods 2008;5:535-8.
21. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010;16:5222-32.
22. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123-9.
23. Sherman ME, Rimm DL, Yang XHR, Chatterjee N, Brinton LA, Lissowska J, et al. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 2007;121: 1079-85.
24. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, et al. Hormonal markers in breast cancer: Coexpression, relationship with pathologic characteristics, and risk factor associations in a populationbased study. Cancer Res 2007;67:10608-17.
25. Sun X, Sandhu R, Figueroa JD, Gierach GL, Sherman ME, Troester MA. Benign breast tissue composition in breast cancer patients: associationwith risk factors, clinical variables, and gene expression. Cancer Epidemiol Biomarkers Prev 2014;23:2810-8.
26. Festa F, Rollins SM, Vattem K, Hathaway M, Lorenz P, Mendoza EA, et al. Robust microarray production of freshly expressed proteins in a human milieu. Proteomics Clin Appl 2013;7:372-7.
27. Wang J, Barker K, Steel J, Park J, Saul J, Festa F, et al. A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics Clin Appl 2013;7:378-83.
28. Montor WR, Huang J, Hu YH, Hainsworth E, Lynch S, Kronish JW, et al. Genome-wide study of pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays. Infect Immun 2009;77:4877-86.
29. Wallstrom G, Anderson KS, LaBaer J. Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev 2013;22:747-55.
30. Ramachandran N, Anderson KS, Raphael JV, Hainsworth E, Sibani S, Montor WR, et al. Tracking humoral responses using self assembling protein microarrays. Proteomics Clin Appl 2008;2:1518-27.
31. Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
32. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972;34:187-220.
33. Reuschenbach M, Doeberitz MV, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009;58:1535-44.
34. Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep 2013;3:2652.
35. Li CI, Mirus JE, Zhang YZ, Ramirez AB, Ladd JJ, Prentice RL, et al. Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study. Breast Cancer Res Treat 2012;135:611-8.
36. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
37. Lacombe J, Mange A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, et al. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer 2013; 132:1105-13.
38. Cabezon T, Gromova I, Gromov P, Serizawa R, Wielenga VT, Kroman N, et al. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics 2013;12:381-94.
39. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang SL, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94: 1914-8.
40. Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Ambrosone CB, et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE 2012;7:9.
41. Line A, Stengrevics A, Slucka Z, Li G, Jankevics E, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer 2002;86:1824-30.
42. Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun Rev 2011;10:509-13.
43. Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci 2006; 97:380-6.
44. Reddy BA, van der Knaap JA, Bot AGM, Mohd-Sarip A, Dekkers DHW, Timmermans MA, et al. Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization. Mol Cell 2014;53: 458-70.
45. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
46. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
47. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011;22:383-9.
48. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109: 25-32.
49. Grigoriadis A, CaballeroOL,Hoek KS, da Silva L, Chen YT, Shin SJ, et al. CTX antigen expression in human breast cancer. Proc Natl Acad Sci U S A 2009;106:13493-8.
50. Gnjatic S, Ritter E, Buchler MW, Giese NA, Brors B, Frei C, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010;107:5088-93.
51. Langer C, Marcucci G, Holland KB, Radmacher MD,Maharry K, Paschka P, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and MicroRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2009;27:3198-204.
52. Schwind S, Marcucci G, Kohlschmidt J, RadmacherMD, Mrozek K, Maharry K, et al.Low expression ofMN1associates with better treatment response in older patients with de novo cytogenetically normal acutemyeloid leukemia. Blood 2011;118:4188-98.
53. Blixt O, Clo E, Nudelman AS, Sorensen KK, Clausen T, Wandall HH, et al. A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res 2010;9:5250-61.
54. Whelan SA, Lu M, He JB, Yan WH, Saxton RE, Faull KF, et al. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res 2009;8:4151-60.
55. Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I,Migliorini P, et al. Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011;10:105-12.
56. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, et al. Cancer biomarkers defined by autoantibody signatures to aberrant Oglycopeptide epitopes. Cancer Res 2010;70:1306-13.
57. Yu X, Woolery AR, Luong P, Hao YH, Grammel M, Westcott N, et al. Copper-catalyzed azide-alkyne cycloaddition (click chemistry)-based detection of global pathogen-host AMPylation on self-assembled human protein microarrays. Mol Cell Proteomics 2014;13:3164-76.